Research has shown that the hypomethylation agent (HMA) decitabine can upregulate the level of ICAM-1(CD54) and CD48 on AML cells, thereby activating NKs to kill leukemia cells while reversing immune evasion by leukemia cells [118, 119]. This evidence concerns the gene ICAM1 and acute myeloid leukemia.